Acta Med. 2009, 52: 15-18

https://doi.org/10.14712/18059694.2016.101

Mood Stabilizer Therapy and Pravastatin: Higher Risk for Adverse Skin Reactions?

Alice Waldera, Pierre Baumannb

aPsychiatric Hospital Sanatorium Kilchberg, Alte Landstrasse 70–84, CH-8802 Kilchberg, Switzerland
bDepartment of Psychiatry, Vaudois University Hospital Centre (DP-CHUV), Site de Cery, CH-1008 Prilly-Lausanne, Switzerland

Received October 1, 2008
Accepted April 1, 2009

References

1. Chan HH, Wing Y, Su R, Van Krevel, Lee S. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord. 2000; 57(1–3):107–13. <https://doi.org/10.1016/S0165-0327(99)00064-6>
2. Christen S, Gueissaz F, Anex R, Zullino DF. Acute generalized exanthematous pustulosis induced by olanzapine. Acta Medica (Hradec Kralove) 2006; 49(1): 75–6. <https://doi.org/10.14712/18059694.2017.114>
3. Degner D, Grohmann R, Kropp S, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 Suppl 1:39–45.
4. Duggal MK, Singh A, Arunabh, Lolis JD, Guzik HJ. Olanzapine-induced vasculitis. Am J Geriatr Pharmacother. 2005; 3(1):21–4. <https://doi.org/10.1016/j.amjopharm.2005.03.003>
5. Jhirwal OP, Parsad D, Basu D. Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int J Dermatol. 2004; 43(10):778–9. <https://doi.org/10.1111/j.1365-4632.2004.02255.x>
6. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology. 1993; 186(4):248–52. <https://doi.org/10.1159/000247363>
7. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51(8):480–51. <https://doi.org/10.1177/070674370605100803>
8. Proksch E. Antilipemic drug-induced skin manifestations. Hautarzt 1995; 46(2): 76–80. <https://doi.org/10.1007/s001050050213>
9. Sartorius N, Baghai TC, Baldwin DS, et al. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol. 2007; 10 Suppl 1:1–207. <https://doi.org/10.1017/S1461145707008255>
10. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006; 67 Suppl 6:16–22.
11. Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol. 2003; 4(1):21–30. <https://doi.org/10.2165/00128071-200304010-00003>
12. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51(8):480–51. <https://doi.org/10.1177/070674370605100803>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive